financetom
Business
financetom
/
Business
/
IGM Financial Says March 2024 Assets Under Management & Advertisement Rose from February
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
IGM Financial Says March 2024 Assets Under Management & Advertisement Rose from February
Apr 3, 2024 11:31 AM

02:03 PM EDT, 04/03/2024 (MT Newswires) -- IGM Financial ( IGIFF ) Wednesday reported total assets under management and advisement of $252.2 billion on March 31, compared with $247.5 billion on Feb. 29 and $234.1 billion at March 31, 2023.

For IGM Financial ( IGIFF ), assets under management & advisement were up 1.9% in the month; total net outflows were $240 million compared to net inflows of $102 million in March 2023. Investment fund net redemptions were $159 million compared to net redemptions of $116 million in March 2023.

IG Wealth Management showed assets under advisement of $128 billion were up 2.1% in the month, and total net outflows were $46 million compared to net outflows of $14 million in March 2023.

For Mackenzie, assets under management of $203.7 billion were up 1.5% in the month. Investment fund net redemptions were $26 million compared to net sales of $94 million in March 2023, and total net redemptions were $193 million compared to net sales of $116 million in March 2023.

Price: 34.10, Change: -0.09, Percent Change: -0.26

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Pfizer Says Phase 3 Trial of Abrysvo for Respiratory Syncytial Virus Disease Meets Primary Endpoints
Pfizer Says Phase 3 Trial of Abrysvo for Respiratory Syncytial Virus Disease Meets Primary Endpoints
Apr 9, 2024
08:57 AM EDT, 04/09/2024 (MT Newswires) -- Pfizer ( PFE ) said Tuesday that its current pivotal phase 3 trial of Abrysvo against placebo in participants aged 18 to 59 years met primary endpoints. The patients were at an increased risk of developing respiratory syncytial virus-associated lower respiratory tract disease, the company said. In the trial, patients attained at least...
Google Introduces Arm-Based Data Center Processor
Google Introduces Arm-Based Data Center Processor
Apr 9, 2024
08:51 AM EDT, 04/09/2024 (MT Newswires) -- Alphabet's (GOOG, GOOGL) Google ( GOOG ) on Tuesday introduced its first custom Arm-based processor designed for data centers. The chip, called Axion, provides up to 30% better performance compared with the fastest general-purpose Arm-based instances available in the cloud today, Google ( GOOG ) said in a blog post. Google ( GOOG...
Pfizer's RSV Vaccine Meets Primary Endpoints in Study of Participants Under 60 Years; Seeks Expanded Access
Pfizer's RSV Vaccine Meets Primary Endpoints in Study of Participants Under 60 Years; Seeks Expanded Access
Apr 9, 2024
08:49 AM EDT, 04/09/2024 (MT Newswires) -- Pfizer ( PFE ) said key data from an ongoing phase 3 clinical trial of its Abrysvo vaccine, which the pharmaceutical giant is developing for the treatment of respiratory syncytial virus, or RSV, met endpoints and it's going to seek wider access for the shot. The study evaluating a single dose of the...
Alkermes Says Potential Narcolepsy Drug Improves Wakefulness in Phase 1b Study
Alkermes Says Potential Narcolepsy Drug Improves Wakefulness in Phase 1b Study
Apr 9, 2024
08:49 AM EDT, 04/09/2024 (MT Newswires) -- Alkermes ( ALKS ) said Tuesday that its phase 1b study of ALKS 2680, a once-daily potential treatment for narcolepsy, showed enhanced wakefulness in patients with narcolepsy type 2 and idiopathic hypersomnia. ALKS 2680 showed clinically meaningful and statistically significant improvements in mean sleep latency compared with placebo across all doses tested in...
Copyright 2023-2026 - www.financetom.com All Rights Reserved